IBS‑C is defined as belly pain (abdominal pain) associated with constipation. The symptoms of IBS‑C are defined as long-lasting and keep coming back. Those suffering from IBS‑C also have hard or lumpy stools at least 25% of the time, and loose or watery stools less than 25% of the time.
The global IBS-C Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2022-2027.
The global IBS-C Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global IBS-C Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
The important driver increasing growth in the Global Irritable Bowel Syndrome with Constipation drugs Market are modern dietary habits that are having adverse effects on the human body. Some of the dietary habits leading to constipation include high intake of foods like insoluble fiber, grains, milk, fried foods, etc. Excessive intake of caffeine and alcohol increases excretion, and this loss of water through urination can also lead to IBS.
Geographical Analysis:
Based on region, the global IBS-C Drug market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global IBS-C Drug market are
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma
Astellas Pharmaceuticals
Ardelyx
Synthetic Biologics
Teva Pharmaceutical Industries
Bama-Geve
Ferring BV
Ironwood Pharmaceuticals
Salix Pharmaceuticals
Norgine
Prometheus Laboratories
Actavis Nordic
Albireo Pharma
Yuhan Corp
Astrazeneca
The Menarini Group
Ono Pharmaceutical
Segment by Type
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global IBS-C Drug market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global IBS-C Drug market.
• The market share of the global IBS-C Drug market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global IBS-C Drug market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global IBS-C Drug market.
The global IBS-C Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2022-2027.
The global IBS-C Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global IBS-C Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
The important driver increasing growth in the Global Irritable Bowel Syndrome with Constipation drugs Market are modern dietary habits that are having adverse effects on the human body. Some of the dietary habits leading to constipation include high intake of foods like insoluble fiber, grains, milk, fried foods, etc. Excessive intake of caffeine and alcohol increases excretion, and this loss of water through urination can also lead to IBS.
Geographical Analysis:
Based on region, the global IBS-C Drug market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global IBS-C Drug market are
Catalent Pharmaceuticals Solutions
Nestle
Abbott Laboratories
Synergy Pharmaceuticals
Sucampo Pharmaceuticals
Novartis Pharma
Astellas Pharmaceuticals
Ardelyx
Synthetic Biologics
Teva Pharmaceutical Industries
Bama-Geve
Ferring BV
Ironwood Pharmaceuticals
Salix Pharmaceuticals
Norgine
Prometheus Laboratories
Actavis Nordic
Albireo Pharma
Yuhan Corp
Astrazeneca
The Menarini Group
Ono Pharmaceutical
Segment by Type
Linaclotide
Lubiprostone
Osmotic Laxatives
Stimulant Laxatives
Other
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global IBS-C Drug market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global IBS-C Drug market.
• The market share of the global IBS-C Drug market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global IBS-C Drug market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global IBS-C Drug market.
1 IBS-C Drug Market Overview
1.1 IBS-C Drug Product Scope
1.2 IBS-C Drug Segment by Type
1.2.1 Global IBS-C Drug Sales by Type (2016 & 2021 & 2027)
1.2.2 Linaclotide
1.2.3 Lubiprostone
1.2.4 Osmotic Laxatives
1.2.5 Stimulant Laxatives
1.2.6 Other
1.3 IBS-C Drug Segment by Application
1.3.1 Global IBS-C Drug Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 IBS-C Drug Market Estimates and Forecasts (2016-2027)
1.4.1 Global IBS-C Drug Market Size in Value Growth Rate (2016-2027)
1.4.2 Global IBS-C Drug Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global IBS-C Drug Price Trends (2016-2027)
2 IBS-C Drug Estimates and Forecasts by Region
2.1 Global IBS-C Drug Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global IBS-C Drug Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global IBS-C Drug Sales Market Share by Region (2016-2021)
2.2.2 Global IBS-C Drug Revenue Market Share by Region (2016-2021)
2.3 Global IBS-C Drug Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global IBS-C Drug Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global IBS-C Drug Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America IBS-C Drug Estimates and Projections (2016-2027)
2.4.2 Europe IBS-C Drug Estimates and Projections (2016-2027)
2.4.3 China IBS-C Drug Estimates and Projections (2016-2027)
2.4.4 Japan IBS-C Drug Estimates and Projections (2016-2027)
2.4.5 Southeast Asia IBS-C Drug Estimates and Projections (2016-2027)
2.4.6 India IBS-C Drug Estimates and Projections (2016-2027)
3 Global IBS-C Drug Competition Landscape by Players
3.1 Global Top IBS-C Drug Players by Sales (2016-2021)
3.2 Global Top IBS-C Drug Players by Revenue (2016-2021)
3.3 Global IBS-C Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in IBS-C Drug as of 2020)
3.4 Global IBS-C Drug Average Price by Company (2016-2021)
3.5 Manufacturers IBS-C Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global IBS-C Drug Market Size by Type
4.1 Global IBS-C Drug Historic Market Review by Type (2016-2021)
4.1.1 Global IBS-C Drug Sales Market Share by Type (2016-2021)
4.1.2 Global IBS-C Drug Revenue Market Share by Type (2016-2021)
4.1.3 Global IBS-C Drug Price by Type (2016-2021)
4.2 Global IBS-C Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global IBS-C Drug Sales Forecast by Type (2022-2027)
4.2.2 Global IBS-C Drug Revenue Forecast by Type (2022-2027)
4.2.3 Global IBS-C Drug Price Forecast by Type (2022-2027)
5 Global IBS-C Drug Market Size by Application
5.1 Global IBS-C Drug Historic Market Review by Application (2016-2021)
5.1.1 Global IBS-C Drug Sales Market Share by Application (2016-2021)
5.1.2 Global IBS-C Drug Revenue Market Share by Application (2016-2021)
5.1.3 Global IBS-C Drug Price by Application (2016-2021)
5.2 Global IBS-C Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global IBS-C Drug Sales Forecast by Application (2022-2027)
5.2.2 Global IBS-C Drug Revenue Forecast by Application (2022-2027)
5.2.3 Global IBS-C Drug Price Forecast by Application (2022-2027)
6 North America IBS-C Drug Market Facts & Figures
6.1 North America IBS-C Drug Sales by Company
6.1.1 North America IBS-C Drug Sales by Company (2016-2021)
6.1.2 North America IBS-C Drug Revenue by Company (2016-2021)
6.2 North America IBS-C Drug Sales Breakdown by Type
6.2.1 North America IBS-C Drug Sales Breakdown by Type (2016-2021)
6.2.2 North America IBS-C Drug Sales Breakdown by Type (2022-2027)
6.3 North America IBS-C Drug Sales Breakdown by Application
6.3.1 North America IBS-C Drug Sales Breakdown by Application (2016-2021)
6.3.2 North America IBS-C Drug Sales Breakdown by Application (2022-2027)
7 Europe IBS-C Drug Market Facts & Figures
7.1 Europe IBS-C Drug Sales by Company
7.1.1 Europe IBS-C Drug Sales by Company (2016-2021)
7.1.2 Europe IBS-C Drug Revenue by Company (2016-2021)
7.2 Europe IBS-C Drug Sales Breakdown by Type
7.2.1 Europe IBS-C Drug Sales Breakdown by Type (2016-2021)
7.2.2 Europe IBS-C Drug Sales Breakdown by Type (2022-2027)
7.3 Europe IBS-C Drug Sales Breakdown by Application
7.3.1 Europe 145 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 145 Sales Breakdown by Application (2022-2027)
8 China IBS-C Drug Market Facts & Figures
8.1 China IBS-C Drug Sales by Company
8.1.1 China IBS-C Drug Sales by Company (2016-2021)
8.1.2 China IBS-C Drug Revenue by Company (2016-2021)
8.2 China IBS-C Drug Sales Breakdown by Type
8.2.1 China IBS-C Drug Sales Breakdown by Type (2016-2021)
8.2.2 China IBS-C Drug Sales Breakdown by Type (2022-2027)
8.3 China IBS-C Drug Sales Breakdown by Application
8.3.1 China 174 Sales Breakdown by Application (2016-2021)
8.3.2 China 174 Sales Breakdown by Application (2022-2027)
9 Japan IBS-C Drug Market Facts & Figures
9.1 Japan IBS-C Drug Sales by Company
9.1.1 Japan IBS-C Drug Sales by Company (2016-2021)
9.1.2 Japan IBS-C Drug Revenue by Company (2016-2021)
9.2 Japan IBS-C Drug Sales Breakdown by Type
9.2.1 Japan IBS-C Drug Sales Breakdown by Type (2016-2021)
9.2.2 Japan IBS-C Drug Sales Breakdown by Type (2022-2027)
9.3 Japan IBS-C Drug Sales Breakdown by Application
9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)
10 Southeast Asia IBS-C Drug Market Facts & Figures
10.1 Southeast Asia IBS-C Drug Sales by Company
10.1.1 Southeast Asia IBS-C Drug Sales by Company (2016-2021)
10.1.2 Southeast Asia IBS-C Drug Revenue by Company (2016-2021)
10.2 Southeast Asia IBS-C Drug Sales Breakdown by Type
10.2.1 Southeast Asia IBS-C Drug Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia IBS-C Drug Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia IBS-C Drug Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)
11 India IBS-C Drug Market Facts & Figures
11.1 India IBS-C Drug Sales by Company
11.1.1 India IBS-C Drug Sales by Company (2016-2021)
11.1.2 India IBS-C Drug Revenue by Company (2016-2021)
11.2 India IBS-C Drug Sales Breakdown by Type
11.2.1 India IBS-C Drug Sales Breakdown by Type (2016-2021)
11.2.2 India IBS-C Drug Sales Breakdown by Type (2022-2027)
11.3 India IBS-C Drug Sales Breakdown by Application
11.3.1 India IBS-C Drug Sales Breakdown by Application (2016-2021)
11.3.2 India IBS-C Drug Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in IBS-C Drug Business
12.1 Catalent Pharmaceuticals Solutions
12.1.1 Catalent Pharmaceuticals Solutions Corporation Information
12.1.2 Catalent Pharmaceuticals Solutions Business Overview
12.1.3 Catalent Pharmaceuticals Solutions IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Catalent Pharmaceuticals Solutions IBS-C Drug Products Offered
12.1.5 Catalent Pharmaceuticals Solutions Recent Development
12.2 Nestle
12.2.1 Nestle Corporation Information
12.2.2 Nestle Business Overview
12.2.3 Nestle IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Nestle IBS-C Drug Products Offered
12.2.5 Nestle Recent Development
12.3 Abbott Laboratories
12.3.1 Abbott Laboratories Corporation Information
12.3.2 Abbott Laboratories Business Overview
12.3.3 Abbott Laboratories IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Abbott Laboratories IBS-C Drug Products Offered
12.3.5 Abbott Laboratories Recent Development
12.4 Synergy Pharmaceuticals
12.4.1 Synergy Pharmaceuticals Corporation Information
12.4.2 Synergy Pharmaceuticals Business Overview
12.4.3 Synergy Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Synergy Pharmaceuticals IBS-C Drug Products Offered
12.4.5 Synergy Pharmaceuticals Recent Development
12.5 Sucampo Pharmaceuticals
12.5.1 Sucampo Pharmaceuticals Corporation Information
12.5.2 Sucampo Pharmaceuticals Business Overview
12.5.3 Sucampo Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Sucampo Pharmaceuticals IBS-C Drug Products Offered
12.5.5 Sucampo Pharmaceuticals Recent Development
12.6 Novartis Pharma
12.6.1 Novartis Pharma Corporation Information
12.6.2 Novartis Pharma Business Overview
12.6.3 Novartis Pharma IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Novartis Pharma IBS-C Drug Products Offered
12.6.5 Novartis Pharma Recent Development
12.7 Astellas Pharmaceuticals
12.7.1 Astellas Pharmaceuticals Corporation Information
12.7.2 Astellas Pharmaceuticals Business Overview
12.7.3 Astellas Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Astellas Pharmaceuticals IBS-C Drug Products Offered
12.7.5 Astellas Pharmaceuticals Recent Development
12.8 Ardelyx
12.8.1 Ardelyx Corporation Information
12.8.2 Ardelyx Business Overview
12.8.3 Ardelyx IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Ardelyx IBS-C Drug Products Offered
12.8.5 Ardelyx Recent Development
12.9 Synthetic Biologics
12.9.1 Synthetic Biologics Corporation Information
12.9.2 Synthetic Biologics Business Overview
12.9.3 Synthetic Biologics IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Synthetic Biologics IBS-C Drug Products Offered
12.9.5 Synthetic Biologics Recent Development
12.10 Teva Pharmaceutical Industries
12.10.1 Teva Pharmaceutical Industries Corporation Information
12.10.2 Teva Pharmaceutical Industries Business Overview
12.10.3 Teva Pharmaceutical Industries IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Teva Pharmaceutical Industries IBS-C Drug Products Offered
12.10.5 Teva Pharmaceutical Industries Recent Development
12.11 Bama-Geve
12.11.1 Bama-Geve Corporation Information
12.11.2 Bama-Geve Business Overview
12.11.3 Bama-Geve IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Bama-Geve IBS-C Drug Products Offered
12.11.5 Bama-Geve Recent Development
12.12 Ferring BV
12.12.1 Ferring BV Corporation Information
12.12.2 Ferring BV Business Overview
12.12.3 Ferring BV IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Ferring BV IBS-C Drug Products Offered
12.12.5 Ferring BV Recent Development
12.13 Ironwood Pharmaceuticals
12.13.1 Ironwood Pharmaceuticals Corporation Information
12.13.2 Ironwood Pharmaceuticals Business Overview
12.13.3 Ironwood Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Ironwood Pharmaceuticals IBS-C Drug Products Offered
12.13.5 Ironwood Pharmaceuticals Recent Development
12.14 Salix Pharmaceuticals
12.14.1 Salix Pharmaceuticals Corporation Information
12.14.2 Salix Pharmaceuticals Business Overview
12.14.3 Salix Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Salix Pharmaceuticals IBS-C Drug Products Offered
12.14.5 Salix Pharmaceuticals Recent Development
12.15 Norgine
12.15.1 Norgine Corporation Information
12.15.2 Norgine Business Overview
12.15.3 Norgine IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Norgine IBS-C Drug Products Offered
12.15.5 Norgine Recent Development
12.16 Prometheus Laboratories
12.16.1 Prometheus Laboratories Corporation Information
12.16.2 Prometheus Laboratories Business Overview
12.16.3 Prometheus Laboratories IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Prometheus Laboratories IBS-C Drug Products Offered
12.16.5 Prometheus Laboratories Recent Development
12.17 Actavis Nordic
12.17.1 Actavis Nordic Corporation Information
12.17.2 Actavis Nordic Business Overview
12.17.3 Actavis Nordic IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.17.4 Actavis Nordic IBS-C Drug Products Offered
12.17.5 Actavis Nordic Recent Development
12.18 Albireo Pharma
12.18.1 Albireo Pharma Corporation Information
12.18.2 Albireo Pharma Business Overview
12.18.3 Albireo Pharma IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.18.4 Albireo Pharma IBS-C Drug Products Offered
12.18.5 Albireo Pharma Recent Development
12.19 Yuhan Corp
12.19.1 Yuhan Corp Corporation Information
12.19.2 Yuhan Corp Business Overview
12.19.3 Yuhan Corp IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.19.4 Yuhan Corp IBS-C Drug Products Offered
12.19.5 Yuhan Corp Recent Development
12.20 Astrazeneca
12.20.1 Astrazeneca Corporation Information
12.20.2 Astrazeneca Business Overview
12.20.3 Astrazeneca IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.20.4 Astrazeneca IBS-C Drug Products Offered
12.20.5 Astrazeneca Recent Development
12.21 The Menarini Group
12.21.1 The Menarini Group Corporation Information
12.21.2 The Menarini Group Business Overview
12.21.3 The Menarini Group IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.21.4 The Menarini Group IBS-C Drug Products Offered
12.21.5 The Menarini Group Recent Development
12.22 Ono Pharmaceutical
12.22.1 Ono Pharmaceutical Corporation Information
12.22.2 Ono Pharmaceutical Business Overview
12.22.3 Ono Pharmaceutical IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.22.4 Ono Pharmaceutical IBS-C Drug Products Offered
12.22.5 Ono Pharmaceutical Recent Development
13 IBS-C Drug Manufacturing Cost Analysis
13.1 IBS-C Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of IBS-C Drug
13.4 IBS-C Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 IBS-C Drug Distributors List
14.3 IBS-C Drug Customers
15 Market Dynamics
15.1 IBS-C Drug Market Trends
15.2 IBS-C Drug Drivers
15.3 IBS-C Drug Market Challenges
15.4 IBS-C Drug Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
1.1 IBS-C Drug Product Scope
1.2 IBS-C Drug Segment by Type
1.2.1 Global IBS-C Drug Sales by Type (2016 & 2021 & 2027)
1.2.2 Linaclotide
1.2.3 Lubiprostone
1.2.4 Osmotic Laxatives
1.2.5 Stimulant Laxatives
1.2.6 Other
1.3 IBS-C Drug Segment by Application
1.3.1 Global IBS-C Drug Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 IBS-C Drug Market Estimates and Forecasts (2016-2027)
1.4.1 Global IBS-C Drug Market Size in Value Growth Rate (2016-2027)
1.4.2 Global IBS-C Drug Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global IBS-C Drug Price Trends (2016-2027)
2 IBS-C Drug Estimates and Forecasts by Region
2.1 Global IBS-C Drug Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global IBS-C Drug Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global IBS-C Drug Sales Market Share by Region (2016-2021)
2.2.2 Global IBS-C Drug Revenue Market Share by Region (2016-2021)
2.3 Global IBS-C Drug Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global IBS-C Drug Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global IBS-C Drug Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America IBS-C Drug Estimates and Projections (2016-2027)
2.4.2 Europe IBS-C Drug Estimates and Projections (2016-2027)
2.4.3 China IBS-C Drug Estimates and Projections (2016-2027)
2.4.4 Japan IBS-C Drug Estimates and Projections (2016-2027)
2.4.5 Southeast Asia IBS-C Drug Estimates and Projections (2016-2027)
2.4.6 India IBS-C Drug Estimates and Projections (2016-2027)
3 Global IBS-C Drug Competition Landscape by Players
3.1 Global Top IBS-C Drug Players by Sales (2016-2021)
3.2 Global Top IBS-C Drug Players by Revenue (2016-2021)
3.3 Global IBS-C Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in IBS-C Drug as of 2020)
3.4 Global IBS-C Drug Average Price by Company (2016-2021)
3.5 Manufacturers IBS-C Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global IBS-C Drug Market Size by Type
4.1 Global IBS-C Drug Historic Market Review by Type (2016-2021)
4.1.1 Global IBS-C Drug Sales Market Share by Type (2016-2021)
4.1.2 Global IBS-C Drug Revenue Market Share by Type (2016-2021)
4.1.3 Global IBS-C Drug Price by Type (2016-2021)
4.2 Global IBS-C Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global IBS-C Drug Sales Forecast by Type (2022-2027)
4.2.2 Global IBS-C Drug Revenue Forecast by Type (2022-2027)
4.2.3 Global IBS-C Drug Price Forecast by Type (2022-2027)
5 Global IBS-C Drug Market Size by Application
5.1 Global IBS-C Drug Historic Market Review by Application (2016-2021)
5.1.1 Global IBS-C Drug Sales Market Share by Application (2016-2021)
5.1.2 Global IBS-C Drug Revenue Market Share by Application (2016-2021)
5.1.3 Global IBS-C Drug Price by Application (2016-2021)
5.2 Global IBS-C Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global IBS-C Drug Sales Forecast by Application (2022-2027)
5.2.2 Global IBS-C Drug Revenue Forecast by Application (2022-2027)
5.2.3 Global IBS-C Drug Price Forecast by Application (2022-2027)
6 North America IBS-C Drug Market Facts & Figures
6.1 North America IBS-C Drug Sales by Company
6.1.1 North America IBS-C Drug Sales by Company (2016-2021)
6.1.2 North America IBS-C Drug Revenue by Company (2016-2021)
6.2 North America IBS-C Drug Sales Breakdown by Type
6.2.1 North America IBS-C Drug Sales Breakdown by Type (2016-2021)
6.2.2 North America IBS-C Drug Sales Breakdown by Type (2022-2027)
6.3 North America IBS-C Drug Sales Breakdown by Application
6.3.1 North America IBS-C Drug Sales Breakdown by Application (2016-2021)
6.3.2 North America IBS-C Drug Sales Breakdown by Application (2022-2027)
7 Europe IBS-C Drug Market Facts & Figures
7.1 Europe IBS-C Drug Sales by Company
7.1.1 Europe IBS-C Drug Sales by Company (2016-2021)
7.1.2 Europe IBS-C Drug Revenue by Company (2016-2021)
7.2 Europe IBS-C Drug Sales Breakdown by Type
7.2.1 Europe IBS-C Drug Sales Breakdown by Type (2016-2021)
7.2.2 Europe IBS-C Drug Sales Breakdown by Type (2022-2027)
7.3 Europe IBS-C Drug Sales Breakdown by Application
7.3.1 Europe 145 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 145 Sales Breakdown by Application (2022-2027)
8 China IBS-C Drug Market Facts & Figures
8.1 China IBS-C Drug Sales by Company
8.1.1 China IBS-C Drug Sales by Company (2016-2021)
8.1.2 China IBS-C Drug Revenue by Company (2016-2021)
8.2 China IBS-C Drug Sales Breakdown by Type
8.2.1 China IBS-C Drug Sales Breakdown by Type (2016-2021)
8.2.2 China IBS-C Drug Sales Breakdown by Type (2022-2027)
8.3 China IBS-C Drug Sales Breakdown by Application
8.3.1 China 174 Sales Breakdown by Application (2016-2021)
8.3.2 China 174 Sales Breakdown by Application (2022-2027)
9 Japan IBS-C Drug Market Facts & Figures
9.1 Japan IBS-C Drug Sales by Company
9.1.1 Japan IBS-C Drug Sales by Company (2016-2021)
9.1.2 Japan IBS-C Drug Revenue by Company (2016-2021)
9.2 Japan IBS-C Drug Sales Breakdown by Type
9.2.1 Japan IBS-C Drug Sales Breakdown by Type (2016-2021)
9.2.2 Japan IBS-C Drug Sales Breakdown by Type (2022-2027)
9.3 Japan IBS-C Drug Sales Breakdown by Application
9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)
10 Southeast Asia IBS-C Drug Market Facts & Figures
10.1 Southeast Asia IBS-C Drug Sales by Company
10.1.1 Southeast Asia IBS-C Drug Sales by Company (2016-2021)
10.1.2 Southeast Asia IBS-C Drug Revenue by Company (2016-2021)
10.2 Southeast Asia IBS-C Drug Sales Breakdown by Type
10.2.1 Southeast Asia IBS-C Drug Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia IBS-C Drug Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia IBS-C Drug Sales Breakdown by Application
10.3.1 Southeast Asia K Units Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Units Sales Breakdown by Application (2022-2027)
11 India IBS-C Drug Market Facts & Figures
11.1 India IBS-C Drug Sales by Company
11.1.1 India IBS-C Drug Sales by Company (2016-2021)
11.1.2 India IBS-C Drug Revenue by Company (2016-2021)
11.2 India IBS-C Drug Sales Breakdown by Type
11.2.1 India IBS-C Drug Sales Breakdown by Type (2016-2021)
11.2.2 India IBS-C Drug Sales Breakdown by Type (2022-2027)
11.3 India IBS-C Drug Sales Breakdown by Application
11.3.1 India IBS-C Drug Sales Breakdown by Application (2016-2021)
11.3.2 India IBS-C Drug Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in IBS-C Drug Business
12.1 Catalent Pharmaceuticals Solutions
12.1.1 Catalent Pharmaceuticals Solutions Corporation Information
12.1.2 Catalent Pharmaceuticals Solutions Business Overview
12.1.3 Catalent Pharmaceuticals Solutions IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Catalent Pharmaceuticals Solutions IBS-C Drug Products Offered
12.1.5 Catalent Pharmaceuticals Solutions Recent Development
12.2 Nestle
12.2.1 Nestle Corporation Information
12.2.2 Nestle Business Overview
12.2.3 Nestle IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Nestle IBS-C Drug Products Offered
12.2.5 Nestle Recent Development
12.3 Abbott Laboratories
12.3.1 Abbott Laboratories Corporation Information
12.3.2 Abbott Laboratories Business Overview
12.3.3 Abbott Laboratories IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Abbott Laboratories IBS-C Drug Products Offered
12.3.5 Abbott Laboratories Recent Development
12.4 Synergy Pharmaceuticals
12.4.1 Synergy Pharmaceuticals Corporation Information
12.4.2 Synergy Pharmaceuticals Business Overview
12.4.3 Synergy Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Synergy Pharmaceuticals IBS-C Drug Products Offered
12.4.5 Synergy Pharmaceuticals Recent Development
12.5 Sucampo Pharmaceuticals
12.5.1 Sucampo Pharmaceuticals Corporation Information
12.5.2 Sucampo Pharmaceuticals Business Overview
12.5.3 Sucampo Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Sucampo Pharmaceuticals IBS-C Drug Products Offered
12.5.5 Sucampo Pharmaceuticals Recent Development
12.6 Novartis Pharma
12.6.1 Novartis Pharma Corporation Information
12.6.2 Novartis Pharma Business Overview
12.6.3 Novartis Pharma IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Novartis Pharma IBS-C Drug Products Offered
12.6.5 Novartis Pharma Recent Development
12.7 Astellas Pharmaceuticals
12.7.1 Astellas Pharmaceuticals Corporation Information
12.7.2 Astellas Pharmaceuticals Business Overview
12.7.3 Astellas Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Astellas Pharmaceuticals IBS-C Drug Products Offered
12.7.5 Astellas Pharmaceuticals Recent Development
12.8 Ardelyx
12.8.1 Ardelyx Corporation Information
12.8.2 Ardelyx Business Overview
12.8.3 Ardelyx IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Ardelyx IBS-C Drug Products Offered
12.8.5 Ardelyx Recent Development
12.9 Synthetic Biologics
12.9.1 Synthetic Biologics Corporation Information
12.9.2 Synthetic Biologics Business Overview
12.9.3 Synthetic Biologics IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Synthetic Biologics IBS-C Drug Products Offered
12.9.5 Synthetic Biologics Recent Development
12.10 Teva Pharmaceutical Industries
12.10.1 Teva Pharmaceutical Industries Corporation Information
12.10.2 Teva Pharmaceutical Industries Business Overview
12.10.3 Teva Pharmaceutical Industries IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Teva Pharmaceutical Industries IBS-C Drug Products Offered
12.10.5 Teva Pharmaceutical Industries Recent Development
12.11 Bama-Geve
12.11.1 Bama-Geve Corporation Information
12.11.2 Bama-Geve Business Overview
12.11.3 Bama-Geve IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Bama-Geve IBS-C Drug Products Offered
12.11.5 Bama-Geve Recent Development
12.12 Ferring BV
12.12.1 Ferring BV Corporation Information
12.12.2 Ferring BV Business Overview
12.12.3 Ferring BV IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.12.4 Ferring BV IBS-C Drug Products Offered
12.12.5 Ferring BV Recent Development
12.13 Ironwood Pharmaceuticals
12.13.1 Ironwood Pharmaceuticals Corporation Information
12.13.2 Ironwood Pharmaceuticals Business Overview
12.13.3 Ironwood Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Ironwood Pharmaceuticals IBS-C Drug Products Offered
12.13.5 Ironwood Pharmaceuticals Recent Development
12.14 Salix Pharmaceuticals
12.14.1 Salix Pharmaceuticals Corporation Information
12.14.2 Salix Pharmaceuticals Business Overview
12.14.3 Salix Pharmaceuticals IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Salix Pharmaceuticals IBS-C Drug Products Offered
12.14.5 Salix Pharmaceuticals Recent Development
12.15 Norgine
12.15.1 Norgine Corporation Information
12.15.2 Norgine Business Overview
12.15.3 Norgine IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Norgine IBS-C Drug Products Offered
12.15.5 Norgine Recent Development
12.16 Prometheus Laboratories
12.16.1 Prometheus Laboratories Corporation Information
12.16.2 Prometheus Laboratories Business Overview
12.16.3 Prometheus Laboratories IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.16.4 Prometheus Laboratories IBS-C Drug Products Offered
12.16.5 Prometheus Laboratories Recent Development
12.17 Actavis Nordic
12.17.1 Actavis Nordic Corporation Information
12.17.2 Actavis Nordic Business Overview
12.17.3 Actavis Nordic IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.17.4 Actavis Nordic IBS-C Drug Products Offered
12.17.5 Actavis Nordic Recent Development
12.18 Albireo Pharma
12.18.1 Albireo Pharma Corporation Information
12.18.2 Albireo Pharma Business Overview
12.18.3 Albireo Pharma IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.18.4 Albireo Pharma IBS-C Drug Products Offered
12.18.5 Albireo Pharma Recent Development
12.19 Yuhan Corp
12.19.1 Yuhan Corp Corporation Information
12.19.2 Yuhan Corp Business Overview
12.19.3 Yuhan Corp IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.19.4 Yuhan Corp IBS-C Drug Products Offered
12.19.5 Yuhan Corp Recent Development
12.20 Astrazeneca
12.20.1 Astrazeneca Corporation Information
12.20.2 Astrazeneca Business Overview
12.20.3 Astrazeneca IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.20.4 Astrazeneca IBS-C Drug Products Offered
12.20.5 Astrazeneca Recent Development
12.21 The Menarini Group
12.21.1 The Menarini Group Corporation Information
12.21.2 The Menarini Group Business Overview
12.21.3 The Menarini Group IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.21.4 The Menarini Group IBS-C Drug Products Offered
12.21.5 The Menarini Group Recent Development
12.22 Ono Pharmaceutical
12.22.1 Ono Pharmaceutical Corporation Information
12.22.2 Ono Pharmaceutical Business Overview
12.22.3 Ono Pharmaceutical IBS-C Drug Sales, Revenue and Gross Margin (2016-2021)
12.22.4 Ono Pharmaceutical IBS-C Drug Products Offered
12.22.5 Ono Pharmaceutical Recent Development
13 IBS-C Drug Manufacturing Cost Analysis
13.1 IBS-C Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of IBS-C Drug
13.4 IBS-C Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 IBS-C Drug Distributors List
14.3 IBS-C Drug Customers
15 Market Dynamics
15.1 IBS-C Drug Market Trends
15.2 IBS-C Drug Drivers
15.3 IBS-C Drug Market Challenges
15.4 IBS-C Drug Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
